Masked T-Cell Engagers and Pasritamig Raise New Hope for Advanced Prostate Cancer Immunotherapy
核心洞察
A new generation of "masked" T cell activators, including VIR-5500, showed an 82% PSA decline and tumor regression in nearly half of high-dose patients with advanced prostate cancer (搜索) in early trials.
Pasritamig (搜索), a bispecific T-cell engager targeting kallikrein 2 (搜索), achieved a 42% PSA response rate with only a 9% rate of cytokine release syndrome in a phase I study.
Masking technology confines immune activation to the tumor, reducing whole-body toxicity and potentially enabling safer, more effective dosing.
Immunotherapy has long been one of the most promising paths in modern cancer treatment, aiming to help the body's own immune system hunt down and destroy cancer cells. Yet many of these treatments carry serious toxicity, limiting how much they can help. A new strategy—"masking" certain drugs so they activate only upon contact with the tumor—is now delivering encouraging early results against prostate cancer (搜索), a disease that has stubbornly resisted existing immunotherapies.
Early clinical trials of these so-called "masked T cell activators" targeted patients with advanced prostate cancer (搜索) that had resisted conventional therapies. Results presented earlier this year at the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology caught the attention of clinicians: among patients receiving the highest doses, 82% saw a drop in their PSA (Prostate-Specific Antigen) levels, a key marker doctors track during prostate cancer follow-up. Nearly half of those high-dose patients also experienced tumor regression, both at the primary prostate site and in metastatic tumors.
How Masked T Cell Activators Work
Cancer cells have developed numerous tricks to evade destruction by the immune system. T cell activators belong to a family of immunotherapies designed to bring immune system warriors—T cells—physically closer to cancer cells. These drugs bind to molecules present on the surfaces of both cell types, forcing proximity that makes T cells unleash toxic substances capable of destroying cancer cells and kickstarting inflammatory processes that promote tumor elimination.
There are now more than 200 different T cell activators, many undergoing trials for tumors ranging from multiple myeloma to leukemia and lung cancer. Their usefulness may extend beyond cancer to persistent viral infections such as hepatitis B. However, the powerful immune reaction they induce can sometimes be too much, resulting in cytokine release syndrome—a severe, dangerous inflammatory syndrome in which the body releases an overwhelming flood of cytokines, potentially leading to life-threatening multi-organ failure.
The "mask" effect changes this calculus. The drug is wrapped in a mask preventing it from interacting with T cells or cancer cells outside the tumor. Once inside the tumor, the mask is broken down by molecules abundant in cancer tissue, unleashing the drug's action precisely where it is needed. Because activation happens only inside the tumor, inflammation—and thus risk—remains confined to the tumor's neighborhood, reducing the threat of serious whole-body reactions. This targeted approach also makes T cell activators more selective for cancer cells, sparing healthy cells that might otherwise wear the same target molecules.
One such medication, VIR-5500, was tested in the recent prostate cancer (搜索) trial. Notably, most patients on the highest VIR-5500 doses reported only mild inflammatory side effects—a strong sign that the masking is working as hoped, given how toxic unmasked T cell activators can be. The slow unmasking also makes dosing simpler and potentially safer, in contrast to standard activators, which require doctors to start with low doses and increase them slowly to avoid sudden immune overreaction.
Pasritamig: A Bispecific T-Cell Engager Targeting Kallikrein 2
Two clinical trials underway at the University of Colorado Anschutz Cancer Center may offer new hope to prostate cancer (搜索) patients whose disease has spread beyond the prostate gland and no longer responds to hormone therapies. The cancer center is a participating site in both national trials, run by the pharmaceutical company Johnson & Johnson.
"The trials are looking at a type of immunotherapy called a bispecific T-cell engager, which links a protein on a T cell with a protein on the tumor with the idea that it will help bring the T-cell to the tumor and activate the T cells, leading to cancer cell killing," says cancer center member Laura Graham, MD, the site principal investigator on both trials. "It is exciting because immunotherapy has been very disappointing in prostate cancer (搜索) so far, but this looks very promising and very well tolerated."
The drug under investigation, pasritamig (搜索), is designed specifically to target prostate cancer (搜索) by attaching T cells to an enzyme called kallikrein 2 (搜索) that is unique to prostate cancer. It is not yet FDA-approved, but results of a phase I study found that it led to a 42% PSA response rate in late-stage metastatic prostate cancer. The phase I study also found the drug was safe, Graham says, with only a 9% rate of cytokine release syndrome, one of the most common side effects of this type of immunotherapy drug.
"It's exciting because prostate cancer (搜索) is very immune cold," says Graham, assistant professor of medical oncology in the CU Anschutz School of Medicine. "If you take prostate cancer biopsies, you typically don't see much immune cell infiltration in them, which is in contrast to melanoma, some lung cancers, or other cancers where there's a lot of immunotherapy response."
Alone or in Combination
One of the clinical trials open at the CU Anschutz Cancer Center is a phase III trial testing the efficacy of pasritamig (搜索) on its own compared to best supportive care; the other is a phase I trial investigating the combination of pasritamig with a second T-cell engager that targets a cancer cell protein called PSMA (搜索) and T-cell protein CD28 (搜索). "The idea is that T cells need two signals to activate, so giving the two drugs will enhance tumor killing," Graham says.
The initial results have Graham and other prostate cancer (搜索) experts excited about the new drug's potential for patients who have often failed other therapies. "My philosophy has always been that the immune system is going to be very important for prostate cancer treatment, and we just haven't figured it out yet," she says. "The reason I'm so excited about this drug is that it's really the first time that we've seen an immunotherapy be effective and well tolerated in prostate cancer. If the early success continues, and this becomes FDA-approved, then I'm hopeful that this is going to be a life-prolonging, well-tolerated medication we can offer our patients."
What Lies Ahead
If further research confirms that masking reliably delivers safer and more potent drugs, the field could expand rapidly. These immunotherapies might be teamed up with more traditional anti-cancer therapies—like chemotherapy or radiation—for a powerful one-two punch. Early promising results have also been reported with other masked T cell activators against prostate cancer (搜索), and trials have already begun to test similar drugs on other cancers, including pancreatic, colorectal, and lung cancers.
These studies remain ongoing, and since phase I trials typically involve limited numbers of patients, it is too early to claim victory. The results also still await peer review and have so far only been shared at oncology conferences. Still, even at this early stage, these developments inspire real hope for treating cancers that have stubbornly resisted existing immunotherapies.
"The trials also give us the chance to learn which patients respond best to the drug and how we can help people respond better," Graham adds. "Are there other combination therapies we should try? What are the mechanisms of resistance?" She also expresses gratitude for the patients taking part in the pasritamig (搜索) trials: "This is a really exciting early step, and we're just going to keep building on it. This has the potential to transform the treatment landscape for prostate cancer (搜索), and we can't do it without them."